Brief: Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial
16/12/2021 12:31
Dec 16 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA THERAPEUTICS ANNOUNCES INITIATION OF AXA1125 LONG
COVID
PHASE 2A CLINICAL TRIAL
* AXCELLA THERAPEUTICS- TOP-LINE DATA READOUT ANTICIPATED BY
MID-2022
Source text for Eikon: ID:nBw8HRMGLa
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment